This is the authors' abstract. We don't add key points for this paper.
Gastrointestinal involvement (GI) is increasingly recognized as a major cause of both morbidity and mortality in systemic sclerosis (SSc). GI complications are common, second only to skin involvement, and affect up to 90% of patients. Although treatment modalities have changed little for upper gut symptoms such as GI reflux, there are emerging treatment modalities for the common lower gut symptoms (constipation and fecal incontinence), which will be reviewed. The important link between reflux and interstitial lung disease in SSc is also addressed. The aim of this review is to help the clinician understand and manage GI symptoms in SSc.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Butt et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: